What is the 13F Pro Quality Score for LXEO?

13F Pro ranks Lexeo Therapeutics, Inc. (LXEO) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View LXEO's current score at https://13fpro.ai/research/LXEO (free sign-up required for the full ranking).

Where does 13F Pro source LXEO data?

All Lexeo Therapeutics, Inc. fundamentals and ownership data come directly from SEC EDGAR. Lexeo Therapeutics, Inc. files with the SEC under CIK 1907108. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is LXEO in?

Lexeo Therapeutics, Inc. (LXEO) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is LXEO research updated on 13F Pro?

LXEO's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Lexeo Therapeutics, Inc.(LXEO)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1907108 LXEO stock profile & AI dashboard →

13F Pro Quality Score

Not in ranked universe

Pending next ranking run

This company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. Rankings refresh on Jan 1, Apr 1, Jul 1, Oct 1.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

LXEO Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Lexeo Therapeutics, Inc. (LXEO), a Healthcare sector company. LXEO is not currently included in 13F Pro's AI-ranked quality universe — this company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. rankings refresh on jan 1, apr 1, jul 1, oct 1. Based on the latest XBRL financial filings (Q1 2026), Lexeo Therapeutics, Inc. reports net income of $-20.2M, free cash flow of $-21.2M. Top institutional holders of LXEO by reported 13-F value include Paradigm Biocapital Advisors, BlackRock,, Affinity Asset Advisors,, based on the most recent SEC filings. LXEO trades on the Nasdaq exchange and files with the SEC under CIK 1907108. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate LXEO daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Lexeo Therapeutics, Inc. directly from SEC EDGAR.

Net Income

Q1 2026

$-20.2M

Free Cash Flow

Q1 2026

$-21.2M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

—FY 2025

FY22 $654.0KFY23 —FY24 —FY25 —

Net Income

-1.7% YoY

$-100.0MFY 2025

FY22 $-59.3MFY23 $-66.4MFY24 $-98.3MFY25 $-100.0M

Operating Income

-3.3% YoY

$-109.3MFY 2025

FY22 $-60.5MFY23 $-68.5MFY24 $-105.8MFY25 $-109.3M

EPS (Diluted)

+39.8% YoY

$-1.86FY 2025

FY22 $-36.36FY23 $-12.40FY24 $-3.09FY25 $-1.86

Total Assets

+82.9% YoY

$268.7MFY 2025

FY22 $97.1MFY23 $139.8MFY24 $146.9MFY25 $268.7M

Op. Cash Flow

-21.5% YoY

$-98.6MFY 2025

FY22 $-54.6MFY23 $-59.5MFY24 $-81.2MFY25 $-98.6M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Revenue	—	—	—	$654.0K	—
Net Income	$-100.0M -1.7%	$-98.3M -48.1%	$-66.4M -12.0%	$-59.3M	—
Operating Income	$-109.3M -3.3%	$-105.8M -54.4%	$-68.5M -13.2%	$-60.5M	—
EPS (Diluted)	$-1.86 +39.8%	$-3.09 +75.1%	$-12.40 +65.9%	$-36.36	—
Total Assets	$268.7M +82.9%	$146.9M +5.1%	$139.8M +44.0%	$97.1M	—
Operating Cash Flow	$-98.6M -21.5%	$-81.2M -36.4%	$-59.5M -9.0%	$-54.6M	—

AI Insight: LXEO Financial Trends

Lexeo's operating losses are stabilizing around $20–$23M quarterly, but equity volatility and persistent cash burn signal ongoing runway constraints.

• Operating losses improved from $34M in Q1 2025 to $22M in Q1 2026, a 35% reduction over four quarters.

• Net losses narrowed from $33M in Q1 2025 to $20M in Q1 2026, indicating operational discipline.

• Operating cash outflow remains consistently negative ($20–$30M/quarter), with no inflection toward cash generation.

⚠ Equity surged $126M Q4 2024 to Q4 2025 (from $117M to $247M), then fell $16M by Q1 2026—volatility suggests financing events, not organic strength.

⚠ Cumulative cash burn Q2 2024–Q1 2026 exceeds $400M against baseline equity, intensifying runway pressure absent revenue.

AI Insight: LXEO Ratio Trends

Lexeo remains deeply unprofitable, but return metrics show steady improvement from Q4 2024 trough toward Q1 2026.

• ROE improved from -88.8% in Q4 2024 to -34.9% in Q1 2026, a 54pp recovery over five quarters.

• ROIC deteriorated sharply Q2–Q4 2024 (-57.1% to -93.7%), then recovered 55pp to -38.6% by Q1 2026.

• ROA narrowed from -70.6% in Q4 2024 to -32.3% in Q1 2026, indicating improving asset efficiency.

⚠ Company remains unprofitable across all return metrics; losses persist despite improvement trajectory.

⚠ Q1 2025 data gaps (ROA, ROIC) and extreme -148.2% ROE suggest material quarterly volatility or reporting anomaly.

Get alerted when LXEO's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Lexeo Therapeutics, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of LXEO

Paradigm Biocapital Advisors LP
$35.5M6,184,134 sh
BlackRock, Inc.
$29.3M5,110,871 sh
Affinity Asset Advisors, LLC
$29.0M5,050,211 sh
RA CAPITAL MANAGEMENT, L.P.
$28.7M5,000,000 sh
JANUS HENDERSON GROUP PLC
$28.5M4,976,429 sh
Vestal Point Capital, LP
$25.7M4,475,000 sh
Frazier Life Sciences Management, L.P.
$25.4M4,424,725 sh
CITADEL ADVISORS LLC
$22.0M3,834,999 sh
ORBIMED ADVISORS LLC
$20.7M3,602,450 sh
STATE STREET CORP
$20.5M3,568,242 sh

Fund	Value	Shares
Paradigm Biocapital Advisors LP	$35.5M	6,184,134
BlackRock, Inc.	$29.3M	5,110,871
Affinity Asset Advisors, LLC	$29.0M	5,050,211
RA CAPITAL MANAGEMENT, L.P.	$28.7M	5,000,000
JANUS HENDERSON GROUP PLC	$28.5M	4,976,429
Vestal Point Capital, LP	$25.7M	4,475,000
Frazier Life Sciences Management, L.P.	$25.4M	4,424,725
CITADEL ADVISORS LLC	$22.0M	3,834,999
ORBIMED ADVISORS LLC	$20.7M	3,602,450
STATE STREET CORP	$20.5M	3,568,242

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put LXEO on your watchlist

Track score changes the day Lexeo Therapeutics, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is LXEO a good stock to buy?

13F Pro's AI-powered analysis of Lexeo Therapeutics, Inc. (LXEO) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for LXEO are available on the LXEO stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own LXEO?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling LXEO. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Lexeo Therapeutics, Inc.'s investment landscape.